Comparative Bioavailability of Trimodal (CTx-1301) Versus Bimodal Dexmethylphenidate Modified-Release Formulations in Adults with Attention-Deficit/Hyperactivity Disorder: A Randomized, Single-Dose, Crossover Study.
CNS DrugsJul 28, 2026 (epub)
Arthur B Straughn, Raul Silva, Michael J Cattaneo et al.
✦ AI-curated · Sources linked
In 30 seconds
This randomized, single-dose, crossover study evaluated the pharmacokinetics of trimodal CTx-1301 versus bimodal dexmethylphenidate (d-MPH XR) in adults with ADHD. The study found that key exposure parameters (C max, AUC last, AUC 0-inf) for CTx-1301 were within the bioequivalence range compared to d-MPH XR. Notably, CTx-1301 showed higher exposure during later intervals (9-16 hours post-dose).
Key findings
- Adjusted geometric mean ratios for CTx-1301 versus d-MPH XR were within the bioequivalence range at both high and low doses.
- CTx-1301 demonstrated higher exposure during later intervals (9-16 hours post-dose) compared to d-MPH XR.
- CTx-1301 was generally well tolerated, with a lower incidence of treatment-emergent adverse events compared to d-MPH XR.
Why it matters
Understanding the pharmacokinetic profiles of ADHD medications is crucial for optimizing treatment strategies. The extended exposure of CTx-1301 may improve symptom control in the late afternoon and evening, addressing a common challenge in ADHD management.